Literature DB >> 7944303

In situ polymerase chain reaction demonstration of JC virus in progressive multifocal leukoencephalopathy, including an index case.

K Ueki1, E P Richardson, J W Henson, D N Louis.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease that is caused by JC papovavirus. The virus can be demonstrated in brains with PML using a variety of techniques. In situ polymerase chain reaction (PCR) is a new method that combines the sensitivity of PCR with the histological localization of in situ hybridization. We here show that in situ PCR can detect JC virus in archival tissue sections of 3 cases of PML, including 1 of the original cases described in 1958 and 1 case that was fixed in formalin for 7 weeks. JC virus DNA was amplified directly on tissue and demonstrated in the characteristic enlarged oligodendrocytes and bizarre astrocytes. These data illustrate the utility of the in situ PCR technique in detecting JC virus in archival sections, including those fixed for prolonged periods, and provide a historical footnote to the original report of PML.

Entities:  

Mesh:

Year:  1994        PMID: 7944303     DOI: 10.1002/ana.410360421

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  3 in total

Review 1.  [Progressive multifocal leukoencephalopathy].

Authors:  J C Wasmuth; A Wasmuth-Pietzuch; U Spengler; J K Rockstroh
Journal:  Med Klin (Munich)       Date:  1999-05-15

2.  JC [corrected] virus detection in human tissue specimens.

Authors:  Huachuan Zheng; Yoshihiro Murai; Mei Hong; Yuko Nakanishi; Kazuhiro Nomoto; Shinji Masuda; Koichi Tsuneyama; Yasuo Takano
Journal:  J Clin Pathol       Date:  2007-01-19       Impact factor: 3.411

3.  High JC virus load in tongue carcinomas may be a risk factor for tongue tumorigenesis.

Authors:  Tomohiko Kutsuna; Huachuan Zheng; Hekmat Osman Abdel-Aziz; Yoshihiro Murai; Koichi Tsuneyama; Isao Furuta; Yasuo Takano
Journal:  Virchows Arch       Date:  2008-02-19       Impact factor: 4.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.